Please use this identifier to cite or link to this item:
|Title:||Pharmacometabolomics of Response to Sertraline and to Placebo in Major Depressive Disorder - Possible Role for Methoxyindole Pathway||Authors:||Zhu, H.
|Issue Date:||17-Jul-2013||Citation:||Zhu, H., Bogdanov, M.B., Boyle, S.H., Matson, W., Sharma, S., Matson, S., Churchill, E., Fiehn, O., Rush, J.A., Krishnan, R.R., Pickering, E., Delnomdedieu, M., Kaddurah-Daouk, R. (2013-07-17). Pharmacometabolomics of Response to Sertraline and to Placebo in Major Depressive Disorder - Possible Role for Methoxyindole Pathway. PLoS ONE 8 (7) : -. ScholarBank@NUS Repository. https://doi.org/10.1371/journal.pone.0068283||Abstract:||Therapeutic response to selective serotonin (5-HT) reuptake inhibitors in Major Depressive Disorder (MDD) varies considerably among patients, and the onset of antidepressant therapeutic action is delayed until after 2 to 4 weeks of treatment. The objective of this study was to analyze changes within methoxyindole and kynurenine (KYN) branches of tryptophan pathway to determine whether differential regulation within these branches may contribute to mechanism of variation in response to treatment. Metabolomics approach was used to characterize early biochemical changes in tryptophan pathway and correlated biochemical changes with treatment outcome. Outpatients with MDD were randomly assigned to sertraline (n = 35) or placebo (n = 40) in a double-blind 4-week trial; response to treatment was measured using the 17-item Hamilton Rating Scale for Depression (HAMD17). Targeted electrochemistry based metabolomic platform (LCECA) was used to profile serum samples from MDD patients. The response rate was slightly higher for sertraline than for placebo (21/35 [60%] vs. 20/40 [50%], respectively, χ2(1) = 0.75, p = 0.39). Patients showing a good response to sertraline had higher pretreatment levels of 5-methoxytryptamine (5-MTPM), greater reduction in 5-MTPM levels after treatment, an increase in 5-Methoxytryptophol (5-MTPOL) and Melatonin (MEL) levels, and decreases in the (KYN)/MEL and 3-Hydroxykynurenine (3-OHKY)/MEL ratios post-treatment compared to pretreatment. These changes were not seen in the patients showing poor response to sertraline. In the placebo group, more favorable treatment outcome was associated with increases in 5-MTPOL and MEL levels and significant decreases in the KYN/MEL and 3-OHKY/MEL; changes in 5-MTPM levels were not associated with the 4-week response. These results suggest that recovery from a depressed state due to treatment with drug or with placebo could be associated with preferential utilization of serotonin for production of melatonin and 5-MTPOL. © 2013 Zhu et al.||Source Title:||PLoS ONE||URI:||http://scholarbank.nus.edu.sg/handle/10635/110608||ISSN:||19326203||DOI:||10.1371/journal.pone.0068283|
|Appears in Collections:||Staff Publications|
Show full item record
Files in This Item:
|2013-pharmacometabolomics_response_sertraline_placebo_major-published.pdf||831.73 kB||Adobe PDF|
checked on Jun 17, 2021
WEB OF SCIENCETM
checked on Jun 8, 2021
checked on Jun 19, 2021
checked on Jun 19, 2021
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.